Keyword: Boehringer Ingelheim
Boehringer just won a skirmish in its high-stakes battle over Humira’s patents, gaining access to documents AbbVie had fought to keep secret.
2018 might be remembered by pharma for a deluge of consumer health castoffs. And one doesn’t really need a crystal ball to see the trend continue.
Boehringer has teamed up for a second year with the Bonnie J. Addario Lung Cancer Foundation to bring holiday cheer directly to lung cancer patients.
As part of its $12.5 billion asset swap with Sanofi, BI will cut 327 of its 2,800 workers in France and create 32 new jobs.
CDMO Lonza is joining a rush of companies looking to cash in on China's eases drug regulations by building a biologics facility there.
Mylan has expanded its valsartan recall to all lots; a Japanese company is buying a Boehringer Ingelheim API plant, plus more manufacturing news.
Following a handful of deals for other biosimilar drugmakers, Pfizer decided to settle its Humira patent fight with AbbVie.
Boehringer is hoping for big things from its Humira biosimilar in the U.S.—so much so that it’s giving up on copycat biologics in other countries.
Johnson & Johnson's Janssen is using Twitter to get the word out about the link between Type 2 diabetes and cardiovascular risks.
With outcomes data showing Farxiga lowers hospitalizations for heart failure or CV deaths against placebo, AZ plans to file for a new FDA label.